Therapeutic drug development program for COVID-19 : Multicenter Study to evaluate efficacy and safety of Demethylchlortetracycline in Patients of COVID-19 - COVID-DMC
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
WHO International Clinical Trials Registry Platform - (2022) vom: 28. Juni Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-08-2020, Last updated: 2022-11-24 |
---|
ICTRP ID: |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
WHO004551370 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | WHO004551370 | ||
003 | DE-627 | ||
005 | 20230425175738.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210507s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)WHO004551370 | ||
035 | |a (UBBS_Klinische_Studien_WHO)JPRN-jRCTs051200049 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Therapeutic drug development program for COVID-19 |b Multicenter Study to evaluate efficacy and safety of Demethylchlortetracycline in Patients of COVID-19 - COVID-DMC |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-08-2020, Last updated: 2022-11-24 | ||
650 | 4 | |a Medical Condition: COVID-19 | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Not yet recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2022) vom: 28. Juni |
773 | 1 | 8 | |g year:2022 |g day:28 |g month:06 |
856 | 4 | 0 | |u https://jrct.niph.go.jp/latest-detail/jRCTs051200049 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2022 |b 28 |c 06 |